Advancing understanding of the mechanisms of antipsychotic-associated cognitive impairment to minimise harm: a call to action

Kelly Allott^{1

2}, Sidhant Chopra³, Jack Rogers⁴, Maria Regina Dauvermann⁴, Scott Richard Clark^{5

6}

Affiliations

¹ Orygen, Parkville, VIC, Australia. kelly.allott@orygen.org.au.
² Centre for Youth Mental Health, The University of Melbourne, Parkville, VIC, Australia. kelly.allott@orygen.org.au.
³ Department of Psychology, Yale University, New Haven, CT, USA.
⁴ Institute for Mental Health, University of Birmingham, Birmingham, UK.
⁵ University of Adelaide, Discipline of Psychiatry, Adelaide, SA, Australia.
⁶ Basil Hetzel Institute, Woodville South, SA, Australia.

PMID: 38454078
PMCID: PMC11412898
DOI: 10.1038/s41380-024-02503-x

Advancing understanding of the mechanisms of antipsychotic-associated cognitive impairment to minimise harm: a call to action

Kelly Allott et al. Mol Psychiatry. 2024 Aug.

. 2024 Aug;29(8):2571-2574.

doi: 10.1038/s41380-024-02503-x. Epub 2024 Mar 7.

Authors

Kelly Allott^{1

2}, Sidhant Chopra³, Jack Rogers⁴, Maria Regina Dauvermann⁴, Scott Richard Clark^{5

6}

Affiliations

¹ Orygen, Parkville, VIC, Australia. kelly.allott@orygen.org.au.
² Centre for Youth Mental Health, The University of Melbourne, Parkville, VIC, Australia. kelly.allott@orygen.org.au.
³ Department of Psychology, Yale University, New Haven, CT, USA.
⁴ Institute for Mental Health, University of Birmingham, Birmingham, UK.
⁵ University of Adelaide, Discipline of Psychiatry, Adelaide, SA, Australia.
⁶ Basil Hetzel Institute, Woodville South, SA, Australia.

PMID: 38454078
PMCID: PMC11412898
DOI: 10.1038/s41380-024-02503-x

No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

**Fig. 1**
Potential mechanisms of the effects of antipsychotics on cognitive function.

See this image and copyright information in PMC

Cited by

Evidence of lithium underuse in bipolar disorder: analysis of lithium and antipsychotic consumption, prediction of future trends, regional disparities and indicators of rational and inappropriate use in Europe.
Bindel LJ, Seifert R. Bindel LJ, et al. Naunyn Schmiedebergs Arch Pharmacol. 2025 Jun 28. doi: 10.1007/s00210-025-04389-0. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2025. PMID: 40580313
MEDICATION EXPOSURE AND NEURODEGENERATIVE DISEASE RISK ACROSS NATIONAL BIOBANKS.
Levine KS, Sargent L, Somerville EN, Pitz V, Price ET, Bandres-Ciga S, Simmonds E, Long RA, Jonson C, Lange LM, Noyce AJ, Escott-Price V, Iwaki H, Keuren-Jensen KV, Ferrucci L, Cookson MR, Singleton A, Nalls M, Leonard H. Levine KS, et al. medRxiv [Preprint]. 2025 Jul 7:2025.07.07.25330740. doi: 10.1101/2025.07.07.25330740. medRxiv. 2025. PMID: 40672496 Free PMC article. Preprint.
Factors Associated With Insight Toward Illness in Patients With Bipolar Disorder Type 1 in Manic Episodes.
Chang YF, Huang SS. Chang YF, et al. Alpha Psychiatry. 2025 Jun 24;26(3):44176. doi: 10.31083/AP44176. eCollection 2025 Jun. Alpha Psychiatry. 2025. PMID: 40630883 Free PMC article.
The impact of aripiprazole on neurocognitive function in individuals at clinical high risk for psychosis: A comparison with olanzapine and non-antipsychotic treatment.
Zeng J, Raballo A, Ye J, Gao Y, Su W, Wei Y, Tang X, Xu L, Hu Y, Zhang D, Cui H, Tang Y, Liu X, Liu H, Chen T, Li C, Wang J, Zhang T. Zeng J, et al. Eur Psychiatry. 2025 May 22;68(1):e69. doi: 10.1192/j.eurpsy.2025.2459. Eur Psychiatry. 2025. PMID: 40401719 Free PMC article.
Glucose homeostasis and cognitive functions in schizophrenia: a systematic review and meta-analysis.
Kancsev A, Virág-Tulassay EÉ, Engh MA, Kiss-Dala S, Horváth AA, Hegyi P, Kéri S. Kancsev A, et al. Sci Rep. 2025 Jul 2;15(1):22898. doi: 10.1038/s41598-025-06225-0. Sci Rep. 2025. PMID: 40594261 Free PMC article.

See all "Cited by" articles

References

1. Fatouros-Bergman H, Cervenka S, Flyckt L, Edman G, Farde L. Meta-analysis of cognitive performance in drug-naive patients with schizophrenia. Schizophrenia Res. 2014;158:156–62. - PubMed
1. Goldberg TE, Goldman RS, Burdick KE, Malhotra AK, Lencz T, Patel RC, et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia. Is it a practice effect? Arch Gen Psychiatry. 2007;64:1115–22. - PubMed
1. Keefe RSE, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry. 2007;64:633–47. - PubMed
1. Husa AP, Rannikko I, Moilanen J, Haapea M, Murray GK, Barnett J, et al. Lifetime use of antipsychotic medication and its relation to change of verbal learning and memory in midlife schizophrenia - An observational 9-year follow-up study. Schizophrenia Res. 2014;158:134–41. - PubMed
1. Allott K, Yuen HP, Baldwin L, O’Donoghue B, Fornito A, Chopra S, et al. Effects of risperidone/paliperidone versus placebo on cognitive functioning over the first 6 months of treatment for psychotic disorder: secondary analysis of a triple-blind randomised clinical trial. Transl Psychiatry. 2023;13:199. - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- PubMed Central
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Advancing understanding of the mechanisms of antipsychotic-associated cognitive impairment to minimise harm: a call to action

Affiliations

Advancing understanding of the mechanisms of antipsychotic-associated cognitive impairment to minimise harm: a call to action

Authors

Affiliations

Conflict of interest statement

Figures

Similar articles

Cited by

References

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Miscellaneous